Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Silver Lining For Pfizer? Celebrex Well-Positioned In NSAID Class

Apr 07 2005

• By Andrew Dove

Related Content

Pfizer Celebrex Continued Marketing Supported By FDA Cmte.

Feb 18 2005

Bextra Pulled From Market, But Pfizer Hopes To Explore Other Options

Apr 07 2005

Celebrex, Bextra Stabilizing After FDA Advisory Committee Review, Pfizer Says

Apr 05 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window